Most adverse events in trials of adenosine triphosphate (ATP) blockers for chronic cough are related to taste, which may inadvertently cause the studies to become unblinded to patients, and a way of measuring this to know the extent of the problem is needed, said Ron Eccles, BSc, PhD, DSc, emeritus professor at Cardiff University.
Most adverse events in trials of adenosine triphosphate (ATP) blockers for chronic cough are related to taste, which may inadvertently cause the studies to become unblinded to patients, and a way of measuring this to know the extent of the problem is needed, said Ron Eccles, BSc, PhD, DSc, emeritus professor at Cardiff University.
Transcript
How are companies developing these therapies determining how effective these therapies actually are in clinical trials?
In order to determine the efficacy of these medicines in clinical trials, you really need to know how unblinded the studies are. We know that in some trials, the highest doses of these ATP antagonists have caused 80% adverse events related to taste. And the investigators have said this may be unblinding the studies. It's not maybe I think—definitely they're becoming unblinded. So I think what we should do is try and measure the blinding. There should be measures put in into the study as at the end of the study, or during the study, what are you being treated with? And if the study is unblinded then we will know it's unblind. Companies are fighting shy of this. They don't want to torpedo their own clinical trials. They don't want to do it. But in science, we want to determine the truth. The truth will get out eventually. So I think we really do need to assess blinding in these clinical trials.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More